Micro Medical Solutions Enhances Leadership Team
Micro Medical Solutions (MMS), a pioneering company in the medical device field, is excited to announce the recent appointments of Vince Burgess and John Dahldorf to its Board of Directors. With their addition, MMS aims to strengthen its governance and successfully navigate the path towards the commercialization of its revolutionary MicroStent™ technology.
Welcoming New Board Members
George Quinoy, who serves as both Chairman of the Board and President & Chief Executive Officer of MMS, expressed his enthusiasm for these appointments. "We are pleased to welcome Vince and John to the MMS Board," he remarked. Their extensive backgrounds in medical device management will play a critical role as MMS approaches FDA review and prepares for its future market launch.
Vince Burgess: A Proven Leader in Medical Devices
Vince Burgess brings a wealth of experience to the MMS Board. His recent role as President and CEO of Acutus Medical, Inc., where he served from 2017 to 2022, showcased his ability to drive company growth in the medical technology sector. Previously, he was a Venture Partner at OrbiMed Advisors, a notable healthcare investment firm, and was one of the founding executives at Volcano Corporation. During his tenure there, he focused on advanced imaging systems, significantly contributing to marketing and business development from 2002 to 2010. His leadership extends beyond these roles, as he currently serves on the Board of Directors for Tela Bio, Inc., and has been involved with several other medical companies in various capacities.
John Dahldorf: Financial Expertise at the Forefront
John Dahldorf complements the Board with over 25 years of financial leadership experience in both public and private healthcare companies. Currently, he is the Chief Financial Officer at Q'Apel Medical, Inc., which specializes in neurovascular devices. Dahldorf's previous contributions as CFO at Volcano Corporation were pivotal during its acquisition by Royal Philips. His extensive finance background also includes significant roles at various organizations, guiding them towards strategic financial growth.
Focus on Innovation and Market Readiness
Both new Board members are expected to leverage their strengths in innovation and financial strategy as MMS advances its mission. Dr. Ron Solar, a Board Member, noted, "Vince and John each bring proven leadership in innovation, commercialization, and financial strategy." Their participation emphasizes MMS's commitment to effective execution as the company readies itself for regulatory approvals and a successful market entry.
MicroStent™ Technology: Revolutionizing Patient Care
The MicroStent™, which recently earned FDA Breakthrough Device Designation, stands as a beacon of hope for patients suffering from Critical Limb Threatening Ischemia (CLTI). It is meticulously designed to enhance blood flow, promote wound healing, and ultimately reduce the potential for amputations in vulnerable patient groups. Currently, the device is undergoing the Premarket Approval (PMA) review process, reinforcing MMS's dedication to improving patient outcomes in the medical field.
About Micro Medical Solutions
Micro Medical Solutions (MMS) focuses on addressing critical challenges in BTK arterial disease, highlighting a significant commitment to medical innovation. Their technology is tailor-made for patients facing the high risk of amputation. This initiative is driven by prevalent global health issues such as diabetes, hypertension, and an aging population. MMS operates at the crucial intersection of clinical demand, regulatory support, and market potential.
Frequently Asked Questions
1. What is the significance of Vince Burgess and John Dahldorf joining the board?
Their expertise in medical devices and finance will help MMS navigate FDA reviews and prepare for market launch.
2. What is the MicroStent™ technology?
The MicroStent™ is designed to enhance blood flow and reduce amputations for patients with Critical Limb Threatening Ischemia.
3. How does Micro Medical Solutions address healthcare needs?
MMS focuses on innovative solutions for treating BTK arterial disease, especially for patients at risk of amputation.
4. What experience does Vince Burgess bring to MMS?
Vince has served as President and CEO of Acutus Medical and held leadership roles at various medical companies, focusing on growth and innovation.
5. Why is financial expertise important for MMS's growth?
Strong financial leadership helps MMS manage resources effectively, especially during crucial stages like FDA approvals and market preparations.
